Results 151 to 160 of about 9,061 (176)
Some of the next articles are maybe not open access.

Overall survival with abemaciclib in early breast cancer☆

open access: yesAnnals of Oncology
Background: Adjuvant abemaciclib combined with endocrine therapy (ET) significantly improved invasive disease-free survival (IDFS) in patients with hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, node-positive, high-risk ...
Laura Testa   +2 more
exaly   +2 more sources

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites

Pharmacological Research, 2022
Alfred H Schinkel   +2 more
exaly  

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib

European Journal of Clinical Pharmacology, 2022
Hitoshi Ando   +2 more
exaly  

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

JTO Clinical and Research Reports, 2021
Vanesa GREGORC   +2 more
exaly  

Home - About - Disclaimer - Privacy